+ Watch EPRS
on My Watchlist
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
these guys just had a merger and named a new CEO ; At least two of the last companies the New CEO ran were sold to phizer. $0.84 is a dealhttp://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=CRXX.O×tamp=20091221221600
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions